Abstract: The present application is directed to siRNA-based silencing of the type II receptor of TGF?. siRNAs that target this receptor abrogate the receptor protein and transcript, TGF?-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGF? type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.

Abstract: The invention provides compact haptic and augmented virtual reality system that produces an augmented reality environment. The system is equipped with software and devices that provide users with stereoscopic visualization and force feedback simultaneously in real time. High resolution, high pixel density, head and hand tracking ability are provided. Well-matched haptics and graphics volumes are realized. Systems of the invention are compact, making use of a standard personal display device, e.g., a computer monitor, as the display driver. Systems of the invention may therefore be inexpensive compared to many conventional virtual reality systems.